187 related articles for article (PubMed ID: 25737167)
1. CD44 as a potential diagnostic tumor marker.
Basakran NS
Saudi Med J; 2015 Mar; 36(3):273-9. PubMed ID: 25737167
[TBL] [Abstract][Full Text] [Related]
2. CD44 and Helicobacter pylori-related colon oncogenesis.
Kountouras J; Kapetanakis N
Saudi Med J; 2015 Oct; 36(10):1249. PubMed ID: 26446341
[No Abstract] [Full Text] [Related]
3. Characterization of a subpopulation of colon cancer cells with stem cell-like properties.
Chu P; Clanton DJ; Snipas TS; Lee J; Mitchell E; Nguyen ML; Hare E; Peach RJ
Int J Cancer; 2009 Mar; 124(6):1312-21. PubMed ID: 19072981
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
6. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
7. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
8. CD44 as a molecular marker to screen cancer stem cells in hypopharyngeal cancer.
Shen C; Xiang M; Nie C; Hu H; Ma Y; Wu H
Acta Otolaryngol; 2013 Nov; 133(11):1219-26. PubMed ID: 23837451
[TBL] [Abstract][Full Text] [Related]
9. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
10. Changes in CD44 expression during carcinogenesis of the mouse colon.
Rudzki Z; LeDuy L; Jothy S
Exp Mol Pathol; 1997 Apr; 64(2):114-25. PubMed ID: 9316589
[TBL] [Abstract][Full Text] [Related]
11. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
12. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
13. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.
Thapa R; Wilson GD
Stem Cells Int; 2016; 2016():2087204. PubMed ID: 27200096
[TBL] [Abstract][Full Text] [Related]
14. Are CD44 variant isoforms involved in human tumour progression?
Günthert U; Stauder R; Mayer B; Terpe HJ; Finke L; Friedrichs K
Cancer Surv; 1995; 24():19-42. PubMed ID: 7553660
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.
Lu M; Zhou L; Zheng X; Quan Y; Wang X; Zhou X; Ren J
Cancer Biomark; 2015; 15(2):163-70. PubMed ID: 25519016
[TBL] [Abstract][Full Text] [Related]
16. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms.
Fox SB; Fawcett J; Jackson DG; Collins I; Gatter KC; Harris AL; Gearing A; Simmons DL
Cancer Res; 1994 Aug; 54(16):4539-46. PubMed ID: 7519124
[TBL] [Abstract][Full Text] [Related]
17. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.
Patrawala L; Calhoun T; Schneider-Broussard R; Li H; Bhatia B; Tang S; Reilly JG; Chandra D; Zhou J; Claypool K; Coghlan L; Tang DG
Oncogene; 2006 Mar; 25(12):1696-708. PubMed ID: 16449977
[TBL] [Abstract][Full Text] [Related]
18. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
19. Regulation of alternative splicing of CD44 in cancer.
Prochazka L; Tesarik R; Turanek J
Cell Signal; 2014 Oct; 26(10):2234-9. PubMed ID: 25025570
[TBL] [Abstract][Full Text] [Related]
20. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
